Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer

Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Res Treat
Hoofdauteurs: Lee, Jiyun, Shim, Joon Ho, Park, Woong-Yang, Kim, Hee Kyung, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Korean Cancer Association 2019
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6333983/
https://ncbi.nlm.nih.gov/pubmed/29807405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.138
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items